Visibility of focal liver lesions: Comparison between kupffer phase of CEUS with sonazoid and hepatobiliary phase of gadoxetic acid–enhanced MRI

Yang, Woo Young; Park, Hee Sun; Kim, Young Jun; Yu, Mi Hye; Jung, Sung Il; Jeon, Hae Jeong

doi:10.1002/jcu.22499

Cited by 9 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantage of considering the Kupffer phase washout as a major imaging feature in Sonazoid CEUS is the improved sensitivity of HCC diagnosis in at-risk patients. According to previous Sonazoid CEUS studies, 7.8%–13.0% of histopathologically proven HCCs with nonrim APHE showed washout only in the Kupffer phase and not in the late vascular phase [ 22 23 24 25 26 ]. Therefore, Kupffer phase washout has the potential to diagnose additional cases of HCC compared with late and mild washout.…”

Section: Questions and Recommendationsmentioning

confidence: 99%

Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

et al. 2023

Self Cite

View full text Add to dashboard Cite

Sonazoid, a second-generation ultrasound contrast agent, was introduced for the diagnosis of hepatic nodules. To clarify the issues with Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma (HCC), the Korean Society of Radiology and Korean Society of Abdominal Radiology collaborated on the guidelines. The guidelines are de novo, evidence-based, and selected using an electronic voting system for consensus. These include imaging protocols, diagnostic criteria for HCC, diagnostic value for lesions that are inconclusive on other imaging results, differentiation from non-HCC malignancies, surveillance of HCC, and treatment response after locoregional and systemic treatment for HCC.

show abstract

Section: Questions and Recommendationsmentioning

confidence: 99%

Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hatanaka et al (2008) found that SZ-CEUS was superior to CECT in diagnostic sensitivity and accuracy of liver malignancies. Yang et al (2017) considered that there was no significant difference between SZ-CEUS and CE-MRI in the detection rate of FLLs. Zhai et al (2019) compared the effectiveness of Sonazoid and Sonovue in FLL assessment in Chinese patients, and the results revealed that Sonazoid's qualitative diagnostic ability was not lower than that of Sono-Vue and that Sonazoid could also significantly improve image quality in the whole liver scan.…”

Section: Introductionmentioning

confidence: 99%

Dynamic Contrast-Enhanced Ultrasonography with Sonazoid for Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma

Li¹,

Han²,

et al. 2022

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

“…Comparing to conventional B-mode and colour Doppler ultrasound imaging, CEUS has higher efficacy in detection and characterization of FLLs [2,3]. Moreover, CEUS has demonstrated similar diagnostic performance to computed tomography (CT) and magnetic resonance imaging (MRI), with advantages including real-time scanning and no radiation exposure [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions

Zhai

Jiang

et al. 2021

Abdom Radiol

View full text Add to dashboard Cite

Objectives To assess the respective diagnostic value of Sonazoid™ and SonoVue® for characterizing FLLs as benign or malignant and the corresponding safety. Methods This prospective Phase 3 study was conducted at 17 centres in China and Korea (May 2014 to April 2015); 424 patients (20 to 80 years) with at least 1 untreated focal liver lesion (FLL) (< 10 cm in diameter) underwent a contrast-enhanced ultrasound (CEUS) examination (218 received Sonazoid of 0.12 μL microbubbles/kg; 206 received SonoVue of 2.4 mL). Three independent blinded readers evaluated pre- and post-contrast images characterising the FLLs as benign or malignant. Results Sonazoid-enhanced and SonoVue-enhanced ultrasound provided a statistically significant improvement in specificity for all 3 readers comparing to unenhanced ultrasound (for Sonazoid: p = 0.0093, < 0.0001, 0.0011; for SonoVue: p = 0.002, 0.03, 0.12, respectively). Difference in accuracy improvement between the 2 groups was within the pre-specified non-inferiority margin of 20% for all 3 readers (6.1%, 95% CI: − 5.0 to 17.2; − 7.5%, 95% CI: − 18.4 to 3.5; − 0.3%, 95% CI: − 11.3 to 10.7). The diagnostic confidence level for all 3 readers increased with post-contrast images relative to pre-contrast images. Both contrast agents were well tolerated. Conclusion Results showed a similar efficacy for Sonazoid™ and SonoVue® in diagnosing FLLs as benign or malignant, and underlined the benefit of CEUS imaging over unenhanced ultrasound imaging in reaching a confident diagnosis without having to refer patients for additional imaging exams.

show abstract

Visibility of focal liver lesions: Comparison between kupffer phase of CEUS with sonazoid and hepatobiliary phase of gadoxetic acid–enhanced MRI

Abstract: The overall visibility of FLLs was comparable between the Kupffer phase of Sonazoid-CEUS and the hepatobiliary-phase images of gadoxetic acid-enhanced MRI, with a discrepancy between the two modalities in 18% of the cases. © 2017 Wiley Periodicals, Inc. J Clin Ultrasound 45:542-550, 2017.

Cited by 9 publications

References 28 publications

Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

Dynamic Contrast-Enhanced Ultrasonography with Sonazoid for Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma

Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions

Contact Info

Product

Resources

About